NASDAQ: CRNX
Crinetics Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRNX

Based on 7 analysts offering 12 month price targets for Crinetics Pharmaceuticals Inc

Min Forecast
$52.00+4.12%
Avg Forecast
$77.29+54.76%
Max Forecast
$105.00+110.25%

Should I buy or sell CRNX stock?

Based on 7 analysts offering ratings for Crinetics Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 42.86%
Buy
4 analysts 57.14%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRNX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CRNX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CRNX stock forecasts and price targets.

CRNX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-12
lockedlocked$00.00+00.00%2026-01-08
lockedlocked$00.00+00.00%2026-01-06
lockedlocked$00.00+00.00%2025-09-30
lockedlocked$00.00+00.00%2025-09-29
Baird
Top 22%
79
BuyMaintains$62.00+24.15%2025-09-26
JP Morgan
Top 4%
97
Strong BuyMaintains$52.00+4.12%2025-09-24

1 of 1

Forecast return on equity

Is CRNX forecast to generate an efficient return?

Company
24.19%
Industry
352.12%
Market
211.34%
CRNX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRNX forecast to generate an efficient return on assets?

Company
21.69%
Industry
122.26%
CRNX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRNX earnings per share forecast

What is CRNX's earnings per share in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
-$5.31
Avg 2 year Forecast
-$3.92
Avg 3 year Forecast
-$1.60

CRNX revenue forecast

What is CRNX's revenue in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$61.6M+3,915.83%
Avg 2 year Forecast
$214.5M+13,870.68%
Avg 3 year Forecast
$551.0M+35,796.42%
CRNX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRNX revenue growth forecast

How is CRNX forecast to perform vs Biotechnology companies and vs the US market?

Company
590.28%
Industry
116.92%
Market
23.08%
CRNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRNX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRNX$49.94$77.29+54.76%Strong Buy
CRSP$49.96$72.50+45.12%Buy
TGTX$29.43$50.75+72.44%Strong Buy
IMVT$26.00$33.00+26.92%Buy
SRRK$44.34$51.20+15.47%Strong Buy

Crinetics Pharmaceuticals Stock Forecast FAQ

Is Crinetics Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: CRNX) stock is to Strong Buy CRNX stock.

Out of 7 analysts, 3 (42.86%) are recommending CRNX as a Strong Buy, 4 (57.14%) are recommending CRNX as a Buy, 0 (0%) are recommending CRNX as a Hold, 0 (0%) are recommending CRNX as a Sell, and 0 (0%) are recommending CRNX as a Strong Sell.

If you're new to stock investing, here's how to buy Crinetics Pharmaceuticals stock.

What is CRNX's earnings growth forecast for 2026-2028?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Crinetics Pharmaceuticals's earnings in 2026 is -$423,097,000.On average, 17 Wall Street analysts forecast CRNX's earnings for 2026 to be -$503,666,908, with the lowest CRNX earnings forecast at -$648,168,202, and the highest CRNX earnings forecast at -$439,396,665. On average, 12 Wall Street analysts forecast CRNX's earnings for 2027 to be -$372,203,753, with the lowest CRNX earnings forecast at -$539,365,219, and the highest CRNX earnings forecast at -$165,396,477.

In 2028, CRNX is forecast to generate -$151,475,844 in earnings, with the lowest earnings forecast at -$403,593,974 and the highest earnings forecast at $98,640,068.

What is CRNX's revenue growth forecast for 2026-2028?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 590.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Crinetics Pharmaceuticals's revenue in 2026 is $1,535,000.On average, 16 Wall Street analysts forecast CRNX's revenue for 2026 to be $5,849,417,693, with the lowest CRNX revenue forecast at $2,334,149,480, and the highest CRNX revenue forecast at $11,213,368,733. On average, 11 Wall Street analysts forecast CRNX's revenue for 2027 to be $20,349,555,088, with the lowest CRNX revenue forecast at $14,105,672,016, and the highest CRNX revenue forecast at $32,379,942,563.

In 2028, CRNX is forecast to generate $52,286,352,758 in revenue, with the lowest revenue forecast at $30,316,045,043 and the highest revenue forecast at $99,446,648,320.

What is CRNX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRNX) forecast ROA is 21.69%, which is lower than the forecast US Biotechnology industry average of 122.26%.

What is CRNX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CRNX price target, the average CRNX price target is $77.29, with the highest CRNX stock price forecast at $105.00 and the lowest CRNX stock price forecast at $52.00.

On average, Wall Street analysts predict that Crinetics Pharmaceuticals's share price could reach $77.29 by Jan 12, 2027. The average Crinetics Pharmaceuticals stock price prediction forecasts a potential upside of 54.76% from the current CRNX share price of $49.94.

What is CRNX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's current Earnings Per Share (EPS) is -$4.52. On average, analysts forecast that CRNX's EPS will be -$5.31 for 2026, with the lowest EPS forecast at -$6.83, and the highest EPS forecast at -$4.63. On average, analysts forecast that CRNX's EPS will be -$3.92 for 2027, with the lowest EPS forecast at -$5.68, and the highest EPS forecast at -$1.74. In 2028, CRNX's EPS is forecast to hit -$1.60 (min: -$4.25, max: $1.04).

What is CRNX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRNX) forecast ROE is 24.19%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.